Provost D - Search Results

1

Cardiotonic agents. Synthesis and cardiovascular properties of novel 2-arylbenzimidazoles and azabenzimidazoles.

Güngör T, Fouquet A, Teulon JM, Provost D, Cazes M, Cloarec A. Güngör T, et al. Among authors: provost d. J Med Chem. 1992 Nov 13;35(23):4455-63. doi: 10.1021/jm00101a024. J Med Chem. 1992. PMID: 1447745

2

Comparison of anticholinergic effects of cibenzoline, disopyramide, and atropine.

Cazes M, Chassaing C, Martinet M, Cloarec A, Provost D, Boucher M, Duchêne-Marullaz P. Cazes M, et al. Among authors: provost d. J Cardiovasc Pharmacol. 1990 Feb;15(2):308-16. doi: 10.1097/00005344-199002000-00019. J Cardiovasc Pharmacol. 1990. PMID: 1689428

3

In vivo pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist.

Cazes M, Provost D, Versigny A, Cloarec A. Cazes M, et al. Among authors: provost d. Eur J Pharmacol. 1995 Sep 15;284(1-2):157-70. doi: 10.1016/0014-2999(95)00395-2. Eur J Pharmacol. 1995. PMID: 8549620

4

Novel 3-(4-piperidinylthio)-1H-indoles as potent nonopioid orally active central analgesics.

Potin D, Parnet V, Teulon JM, Camborde F, Caussade F, Meignen J, Provost D, Cloarec A. Potin D, et al. Among authors: provost d. Bioorg Med Chem Lett. 2000 Apr 17;10(8):805-9. doi: 10.1016/s0960-894x(00)00102-5. Bioorg Med Chem Lett. 2000. PMID: 10782691

5

In vitro and in vivo effects of UP 269-6, a new potent orally active nonpeptide angiotensin II receptor antagonist, on vascular smooth muscle cell proliferation.

Virone-Oddos A, Desangle V, Provost D, Cazes M, Caussade F, Cloarec A. Virone-Oddos A, et al. Among authors: provost d. Br J Pharmacol. 1997 Feb;120(3):488-94. doi: 10.1038/sj.bjp.0700897. Br J Pharmacol. 1997. PMID: 9031754 Free PMC article.

6

Models of cardiovascular disease: measurement of antihypertensive activity in the conscious rat (SHR, DOCA-salt, and Goldblatt hypertension models).

Guillaume P, Provost D, Legrand P, Godes M, Lacroix P. Guillaume P, et al. Among authors: provost d. Curr Protoc Pharmacol. 2009 Mar;Chapter 5:Unit 5.53. doi: 10.1002/0471141755.ph0553s44. Curr Protoc Pharmacol. 2009. PMID: 22294399

7

Gastrointestinal models: intestinal transit, gastric emptying, and ulcerogenic activity in the rat.

Guillaume P, Provost D, Lacroix P. Guillaume P, et al. Among authors: provost d. Curr Protoc Pharmacol. 2008 Sep;Chapter 5:Unit5.3. doi: 10.1002/0471141755.ph0503s42. Curr Protoc Pharmacol. 2008. PMID: 22294224

8

Models of cardiovascular disease: measurement of arrhythmogenic/antiarrhythmic activity in the guinea pig.

Guillaume P, Provost D, Lacroix P. Guillaume P, et al. Among authors: provost d. Curr Protoc Pharmacol. 2009 Mar;Chapter 5:Unit 5.1. doi: 10.1002/0471141755.ph0501s44. Curr Protoc Pharmacol. 2009. PMID: 22294396

9

Basic safety pharmacology: the cardiovascular system.

Lacroix P, Provost D. Lacroix P, et al. Among authors: provost d. Therapie. 2000 Jan-Feb;55(1):63-9. Therapie. 2000. PMID: 10860003 Review.

10

Endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner.

Kalk P, Sharkovska Y, Kashina E, von Websky K, Relle K, Pfab T, Alter M, Guillaume P, Provost D, Hoffmann K, Fischer Y, Hocher B. Kalk P, et al. Among authors: provost d. Hypertension. 2011 Apr;57(4):755-63. doi: 10.1161/HYPERTENSIONAHA.110.163972. Epub 2011 Feb 21. Hypertension. 2011. PMID: 21339476

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

91 results

Search Page

Filters